Skip to main content
. 2021 Sep 7;20:15347354211035450. doi: 10.1177/15347354211035450

Figure 8.

Figure 8.

Annexin-V of proliferative HCT116 andSen-HCT116 cells by flow cytometry. (a) Histogram of HCT116 and Sen-HCT116 treated with 50 µM thymoquinone (TQ) for 24 hours. (b) Histogram of HCT116 and Sen-HCT116 treated with 30 µM costunolide (COS) for 24 hours. (c) Percentages of annexin-v positive cells of HCT116 and Sen-HCT116 treated with 50 µM TQ for 24 hours. (d) Percentages of annexin-v positive cells of HCT116 and Sen-HCT116 treated with 30 µM COS for 24 hours. The data were analyzed with 1-way ANOVA (Tukey’s Multiple Comparison Test). Error bars represent mean ± SD. **P < .01 and ***P < .001 versus control. xxxP < .001 versus HCT116 + TQ or HCT116 + COS. Control refers to proliferative-untreated HCT116. HCT116 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. HCT116 + COS refers to HCT116 treated with 30 µM COS for 24 hours. HCT116 + Dox5 + TQ refers to Sen-HCT116 with 100 nM Dox for 5 days, then treated with 50 µM TQ for 24 hours. HCT116 + Dox5 + COS refers to Sen-HCT116 with 100 nM Dox for 5 days then treated with 30 µM COS for 24 hours. TQ, thymoquinone. COS, costunolide. All assays were done in triplicate at least.